Trinity Biotech plc announced on October 25, 2024, the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This strategic move marks Trinity Biotech's expansion into the oncology diagnostics market. Prostate cancer affects approximately one in eight men in the U.S., with annual diagnosis and treatment costs estimated at over $10 billion.
The EpiCapture test is a urine-based solution designed to reduce the need for repeated invasive prostate biopsies for patients under active surveillance. It utilizes epigenetic analysis to detect DNA methylation patterns indicative of high-grade cancer. A study published in The Journal of Clinical Oncology – Precision Oncology demonstrated that, when combined with the PSA test, EpiCapture's test correctly predicted all high-grade cancers.
Trinity Biotech plans to leverage its 30 years of experience in diagnostic product optimization and manufacturing, along with its New York State Department of Health-certified Immco reference laboratory, to commercialize the EpiCapture test in the US. The initial consideration for the acquisition was approximately $3 million, paid through the issuance of about 1.7 million American Depository Shares (ADS), with an additional $0.5 million contingent on future milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.